Table 1.

Characteristics of women with DCIS by socioeconomic deprivation and urban/rural locations at the time of diagnosis in the Missouri Cancer Registry, 1996–2011

Socioeconomic deprivationUrban/rural location
Lowest tertile, N (%)Highest tertile, N (%)PUrban, N (%)Rural, N (%)P
Number of cases4,3061,9977,0742,121
Age at diagnosis, y
 Mean (SD)59.5 (12.5)62.3 (12.9)<0.000160.1 (12.6)61.7 (12.4)<0.0001
 <501,021 (23.7)360 (18.0)1,595 (22.6)372 (17.5)
 50–591,234 (28.7)481 (24.1)1,918 (27.1)563 (26.5)
 60–691,070 (24.9)541 (27.1)1,809 (25.6)570 (26.9)
 ≥70981 (22.8)615 (30.8)<0.00011,752 (24.8)616 (29.0)<0.0001
Race and ethnicity
 Non-Hispanic white3,989 (92.6)1,458 (73.0)6,013 (85.0)2,052 (96.8)
 Non-Hispanic black194 (4.5)503 (25.2)877 (12.4)38 (1.8)
 Others123 (2.9)36 (1.8)<0.0001184 (2.6)31 (1.5)<0.0001
Length of follow-up, months
 Median (range)77 (2–191)71 (2–191)0.000674 (2–191)78 (2–191)0.001
 6–11294 (6.8)123 (6.2)536 (7.6)88 (4.2)
 12–591,362 (31.6)721 (36.1)2,340 (33.1)709 (33.4)
 60–1191,473 (34.2)688 (34.5)2,415 (34.1)768 (36.2)
 ≥1201,177 (27.3)465 (23.3)0.0011,783 (25.2)556 (26.2)<0.0001
Year of the first DCIS diagnosis
 1996–1999932 (21.6)392 (19.6)1,481 (20.9)418 (19.7)
 2000–20041,411 (32.8)656 (32.9)2,232 (31.6)755 (35.6)
 2005–20091,446 (33.6)722 (36.2)2,409 (34.1)796 (37.5)
 2010–2011517 (12.0)227 (11.4)0.15952 (13.5)152 (7.2)<0.0001
Health insurance
 Private966 (66.9)299 (44.3)1,532 (61.4)301 (47.9)
 Medicare445 (30.8)295 (43.7)842 (33.7)285 (45.3)
 Medicaid or uninsured34 (2.4)81 (12.0)<0.0001122 (4.9)43 (6.8)<0.0001
 Other or missing2,8611,3224,5781,492
Histologic subtype
 Not otherwise specified3,101 (72.0)1,397 (70.0)5,062 (71.6)1,484 (70.0)
 Comedo499 (11.6)274 (13.7)824 (11.7)315 (14.9)
 Papillary291 (6.8)174 (8.7)518 (7.3)167 (7.9)
 Cribriform243 (5.6)82 (4.1)394 (5.6)87 (4.1)
 Solid172 (4.0)70 (3.5)0.01276 (3.9)68 (3.2)<0.0001
Grade
 Well differentiated628 (20.8)291 (22.6)1,063 (21.4)273 (21.5)
 Moderately differentiated1,078 (35.7)452 (35.1)1,800 (36.3)472 (37.1)
 Poorly differentiated1,314 (43.5)546 (42.4)0.052,094 (42.2)526 (41.4)0.83
 Missing1,2867082,117850
Tumor size, cm
 <2.0927 (72.9)467 (70.3)1,604 (71.6)487 (70.8)
 ≥2.0345 (27.1)197 (29.7)0.32635 (28.4)201 (29.2)0.66
 Missing3,0341,3334,8351,433
Estrogen receptor
 Negative304 (16.1)160 (18.9)538 (16.9)175 (20.3)
 Positive1,590 (84.0)686 (81.1)0.052,648 (83.1)687 (79.7)0.02
 Missing2,4121,1513,8881,259
Surgery for first DCIS
 None89 (2.1)64 (3.2)166 (2.4)55 (2.6)
 BCS2,965 (69.1)1,191 (60.0)4,717 (67.0)1,307 (62.1)
 Mastectomy1,237 (28.8)729 (36.7)<0.00012,156 (30.6)744 (35.3)0.0001
 Missing15133515
Surgical margina
 Clear3,874 (96.0)1,730 (95.8)6,337 (96.0)1,794 (95.6)
 Positive162 (4.0)75 (4.2)0.97261 (4.0)82 (4.4)0.42
 Missing166115275175
Radiotherapy for first DCIS
 No1,980 (46.2)1,207 (61.3)3,489 (49.6)1,274 (61.3)
 Yes2,303 (53.8)763 (38.7)<0.00013,545 (50.4)803 (38.7)<0.0001
 Missing23274044
Surgery and radiotherapy for first DCIS
 No surgical treatment89 (2.1)64 (3.2)166 (2.4)55 (2.6)
 BCS alone683 (16.0)442 (22.4)1,220 (17.4)508 (24.4)
 BCS and radiation2,271 (53.1)738 (37.4)3,479 (49.6)776 (37.3)
 Mastectomy1,237 (28.9)729 (37.0)<0.00012,156 (30.7)744 (35.7)<0.0001
 Missing26245338
Weeks from surgery to radiation, mean (SD)b6.2 (3.8)7.2 (4.7)<0.00016.5 (4.2)6.4 (3.8)0.53
Guideline concordant use of endocrine therapyc
 No1,171 (59.6)655 (67.1)2,018 (61.1)689 (67.8)
 Yes794 (40.4)321 (32.9)0.00021,287 (38.9)328 (32.3)0.0001
 Missing1134821437
  • aThe comparison was made in the patients with surgical treatment.

  • bThe analysis was limited to the patients who received radiotherapy following definitive BCS.

  • cThe analysis included the patients with estrogen receptor–positive DCIS and the patients with BCS alone.